COMP <GO>
NDRA vs NXL // EV/EBITDA & P/E VALUATION
ENDRA Life Sciences Inc. (NASDAQ) VS. Nexalin Technology Inc. (NASDAQ) • 15-METRIC TALLY: NDRA 2
— NXL 1
■ METRIC PARITY
LAST: $4.88 (+2.95%) • MKT CAP: $7.3M
valuation
—
LAST: $1.63 (0.00%) • MKT CAP: $1.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NDRA VS. NXL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NDRA | NXL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 79.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 78.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | NXL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.0 | 26.2 | +15.87 | NDRA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.3M | $1.9M | $5.4M | NDRA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NDRA REV | NXL REV | NDRA GROSS % | NXL GROSS % | NDRA FCF | NXL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $301.6K | — | 79.7% | -$5.2M | -$5.0M |
| FY 2024 | $0 | $168.7K | — | 78.3% | -$7.4M | -$3.9M |
| FY 2023 | $0 | $110.7K | — | — | -$9.5M | -$3.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NDRA // BETA —
NXL // BETA —